CJC-1295 DAC vs No DAC: Key Differences for Research
Written bySpartan Research Team
CJC-1295 with DAC and CJC-1295 without DAC are built on the same core GHRH fragment (modified GRF 1-29), but they behave very differently in research models. The difference is one chemical modification, and it changes the half-life from roughly 30 minutes to six to eight days. That’s not a subtle pharmacokinetic variation. It changes the entire research application profile.
🔬 KEY RESEARCH FINDINGS
- One chemical modification changes everything: CJC-1295 with DAC and without DAC share the same core modified GRF 1-29 fragment, but the DAC maleimide group’s albumin-binding mechanism stretches half-life from roughly 30 minutes to 6 to 8 days.
- DAC produces sustained elevation, no DAC produces pulsatile release: The DAC version generates a flat, sustained GH and IGF-1 elevation profile documented out to 10 days post-injection, while the no-DAC version produces a short GH pulse that more closely resembles natural pituitary secretion patterns.
- No-DAC is the standard research pairing with GHRPs: Because CJC-1295 without DAC acts on GHRH receptors and GHRPs like Ipamorelin act on GHS-R1a, the two pathways combine synergistically, and the short half-life of no-DAC matches Ipamorelin’s own short half-life for co-administration timing.
- Administration frequency reflects the pharmacokinetic difference directly: DAC’s multi-day half-life supports weekly or biweekly dosing schedules in research protocols, while no-DAC’s 30 minute half-life requires much more frequent administration to sustain any pulsatile effect.
- Neither version is interchangeable with the other in a research design: Selecting DAC versus no DAC is a design decision about sustained versus pulsatile GH exposure, not a potency or quality tradeoff between two versions of the same compound.
- Teichman SL et al. (2006) conducted a Phase II clinical study of CJC-1295 (with DAC modification) documenting sustained GH and IGF-1 elevation for up to 10 days following a single injection, confirming the albumin-binding mechanism’s pharmacokinetic prediction (PMID 16823353).
- Bowers CY et al. work on GHRPs established the synergistic GH release mechanism when GHRH pathway agonists are combined with GHS-R1a agonists (GHRPs), foundational for understanding why Modified GRF 1-29 / CJC-1295 no DAC combinations with Ipamorelin produce amplified GH pulses (PMID 15467403).
Understanding the DAC modification and what it does explains why both versions exist and when each is the appropriate research tool.
- CJC-1295 with DAC: albumin-binding via maleimide-DAC group, half-life approximately 6-8 days, produces sustained GH/IGF-1 elevation, weekly or biweekly administration in most research protocols.
- CJC-1295 without DAC (Mod GRF 1-29): no albumin binding group, half-life approximately 30 minutes, produces short pulsatile GH stimulation, typically combined with a GHRP (Ipamorelin, GHRP-2) for synergistic GH pulse amplification.
Background: What Both Compounds Are
Both are analogs of GRF 1-29 (growth hormone releasing factor, the first 29 amino acids of endogenous GHRH). The native GRF 1-29 sequence has a short in vivo half-life due to dipeptidyl peptidase IV (DPP-IV) cleavage at the Ala-2 position and other plasma protease activity. CJC-1295 and its variants address this by substituting Ala-2 with D-Ala and making additional amino acid substitutions (at positions 8, 15, and 27) that resist protease cleavage. These modifications extend the no-DAC version’s half-life from about 7 minutes (native GRF 1-29) to about 30 minutes.
The DAC (Drug Affinity Complex) modification goes further. It adds a maleimidopropionic acid group linked to a lysine residue at the C-terminus of the modified GRF 1-29 sequence. The maleimide group reacts rapidly and covalently with the free thiol of Cys-34 on circulating albumin. Once bound to albumin, the peptide effectively inherits albumin’s slow clearance kinetics.
The Albumin Binding Mechanism
Albumin is cleared slowly from circulation primarily because of FcRn (neonatal Fc receptor) recycling. Rather than being degraded after endocytosis, albumin binds FcRn in acidic endosomes and is recycled back to the cell surface, extending its plasma half-life to approximately 19 days in humans. Drug conjugation to albumin is a recognized strategy in pharmaceutical development for extending the half-life of short-lived biologics. The DAC modification applies this principle specifically to CJC-1295.
The Cys-34 reaction is selective: it’s the only free cysteine in the albumin molecule, making it a predictable and specific attachment site. The covalent bond formed (a thioether linkage) is stable under physiological conditions, meaning the CJC-1295-albumin conjugate remains intact throughout the albumin molecule’s lifetime in circulation.
The result in animal research models: CJC-1295 DAC shows a dose-dependent GH response that is sustained for days after a single injection. Plasma GH levels remain elevated compared to vehicle-treated controls for up to a week or more at research doses. IGF-1 (the downstream liver-produced hormone driven by GH) is also elevated persistently.
CJC-1295 No DAC: The Pulsatile Version
Without the albumin-binding modification, CJC-1295 no DAC (also called Modified GRF 1-29, or Mod GRF 1-29) is cleared quickly. The 30-minute half-life means GH stimulation is transient, mimicking the short GHRH pulses that drive natural GH secretion in physiology. Natural GH secretion is pulsatile (pulses roughly every 3-4 hours, amplified during slow-wave sleep), and short-acting GHRH analogs preserve that pattern better than the DAC version.
This is why CJC-1295 no DAC is almost always combined with a GHRP in research designs. A GHRH analog alone produces a modest GH pulse. Adding a GHS-R1a agonist like Ipamorelin through a separate receptor pathway produces a synergistic response significantly larger than either compound alone. The timing matters: both need to be present simultaneously to produce the synergistic pulse. Since both have short half-lives, co-administration makes sense.
The CJC-1295/Ipamorelin blend available through Spartan uses exactly this combination principle, pairing the GHRH analog activity of CJC-1295 no DAC with Ipamorelin’s selective GHS-R1a agonism for amplified GH pulsatility. The Spartan Strong CJC/Tesamorelin blend uses Tesamorelin, another GHRH analog, in a similar framework. Full context on GHRH analog combinations is in the Spartan research library.
Pulsatile vs Sustained GH: Which Research Design Fits?
This is the central question for researchers choosing between the two versions. The answer depends on what biological question you’re asking.
If you’re studying the effects of sustained GH/IGF-1 elevation over time (something like GH replacement biology, body composition changes with continuous GH exposure, or testing GH receptor desensitization), CJC-1295 DAC is more practical. One or two injections per week maintains elevated IGF-1 throughout the study period without daily dosing demands.
If you’re studying pulsatile GH dynamics, GH pulse amplitude regulation, or testing compounds that synergize with GHRH receptor stimulation, CJC-1295 no DAC gives you control over pulse timing and amplitude. You can study how GH pulses interact with feeding, sleep cycles, or other physiological variables by timing no-DAC administration around those events.
If you’re not specifically interested in the GH secretion kinetics and just want to explore downstream GH/IGF-1 effects, either could work, but the different IGF-1 profiles (sustained vs pulsatile elevated) may produce different downstream effects that confound comparison with natural physiology.
Research Observations on GH Receptor Desensitization
One consideration with sustained GH elevation is GH receptor downregulation. Chronic GH receptor activation can reduce receptor density and signaling sensitivity, a form of homologous desensitization. Whether this occurs with CJC-1295 DAC-induced GH elevation at research doses is a relevant question for study design. Animal data on this is limited, but it’s a known phenomenon with exogenous GH administration at pharmacological doses.
Pulsatile GH administration (mimicking natural physiology) tends to be less desensitizing than continuous infusion in the rodent models that have examined this. Whether the difference between pulsatile (no DAC) and sustained (DAC) GHRH analog administration produces measurable desensitization differences at typical research doses hasn’t been extensively characterized.
Practical Research Considerations
CJC-1295 DAC: store lyophilized at -20°C, reconstitute in bacteriostatic water at 1-2 mg/mL, administer 1-2 times per week in rodent protocols. The longer interval simplifies multi-week study logistics. Monitor IGF-1 as the downstream marker of sustained GH activity.
CJC-1295 no DAC: same storage and reconstitution. Administer in conjunction with GHRP of choice (timing together within minutes for maximum synergy). Multiple daily administrations are standard in rodent protocols studying GH pulse dynamics. Useful for experiments where you want precise control over when GH pulses occur.
Both compounds: purity verification by HPLC at 98%+, mass spectrometry confirmation of correct molecular weight. CJC-1295 with DAC: approximately 3647 Da. CJC-1295 without DAC: approximately 3357 Da.
Summary
CJC-1295 with DAC and without DAC are not interchangeable research tools despite sharing a core sequence. The DAC modification creates a compound with week-long duration that’s useful for sustained GH elevation studies. The no-DAC version is a short-acting GHRH agonist best combined with a GHRP for pulsatile GH amplification. Choosing between them is a research design decision based on what GH kinetics you need: sustained and continuous, or short and pulsatile.
Related Research Reading
- Hexarelin: Growth Hormone Secretagogue Mechanisms
- Ipamorelin Research Guide: Selective GH Secretagogue
- Best Peptides for Weight Loss 2026 | Spartan Peptides
- NAD+ vs NMN vs NR: Precursor Comparison for Research
- CJC-1295 + Ipamorelin: The Complete 2026 Research Guide
Research Disclaimer: The information presented in this article is intended for educational and research purposes only. The compounds discussed are research chemicals and are not approved by the FDA for human use, consumption, or therapeutic application. All research must be conducted in accordance with applicable laws and regulations. Spartan Peptides supplies research-grade compounds exclusively for in vitro and laboratory research use.
Written by the Spartan Research Team
Our team of peptide researchers and biochemists reviews every article for scientific accuracy. Learn more about our team →